Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, febuxostat (Adenuric®) cannot be endorsed for use within NHS Wales for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematological malignancies at intermediate to high risk of Tumour Lysis Syndrome (TLS) |
||
|
||
Medicine details |
||
| Medicine name | febuxostat (Adenuric®) | |
| Formulation | 120 mg film-coated tablet | |
| Reference number | 2665 | |
| Indication | Prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematological malignancies at intermediate to high risk of Tumour Lysis Syndrome (TLS) |
|
| Company | A. Menarini Farmaceutica Internazionale SRL | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 27/08/2015 | |